CASTLE BIOSCIENCES, INC. Castle Biosciences, Inc. Stock
Equities
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.54 USD | -1.07% |
|
+6.90% | +9.08% |
| May. 08 | Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing | MT |
| May. 02 | Transcript : Castle Biosciences, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 261M | Sales 2025 * | 261M | Capitalization | 650M |
|---|---|---|---|---|---|
| Net income 2024 * | -45M | Net income 2025 * | -54M | EV / Sales 2024 * | 1.54 x |
| Net cash position 2024 * | 249M | Net cash position 2025 * | 201M | EV / Sales 2025 * | 1.72 x |
| P/E ratio 2024 * |
-14.5
x | P/E ratio 2025 * |
-12.3
x | Employees | 638 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Castle Biosciences, Inc.
More recommendations
More press releases
| 1 day | -1.07% | ||
| 1 week | +6.90% | ||
| Current month | +11.62% | ||
| 1 month | +12.85% | ||
| 3 months | -1.30% | ||
| 6 months | +31.07% | ||
| Current year | +9.08% |
1 week
22.78
25.91
1 month
18.5025.91
Current year
17.4225.91
1 year
9.2626.70
3 years
9.2678.92
5 years
9.26107.69
10 years
9.26107.69
| Managers | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
FOU | Founder | 62 | 07-08-31 |
Franklin Stokes
DFI | Director of Finance/CFO | 54 | 17-11-30 |
Johnson Clare
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
FOU | Founder | 62 | 07-08-31 |
Daniel Bradbury
CHM | Chairman | 62 | 12-08-31 |
G. Cole
BRD | Director/Board Member | 68 | 18-12-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 11 M€ | -6.03% | - | |
| 0.60% | 12 M€ | -.--% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.05% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | +3.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 23.54 | -1.07% | 176,531 |
| 24-05-07 | 23.8 | -2.52% | 328,456 |
| 24-05-06 | 24.41 | +0.33% | 437,349 |
| 24-05-03 | 24.33 | +6.52% | 839,813 |
| 24-05-02 | 22.84 | +3.72% | 322,974 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
Calendar
2024-05-23
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.54
USD
Average target price
34.33
USD
Spread / Average Target
+45.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.08% | 657M | |
| -1.49% | 12.71B | |
| +0.13% | 8.37B | |
| -1.12% | 5.4B | |
| +20.18% | 5.27B | |
| -0.74% | 4.63B | |
| -54.68% | 3.13B | |
| +24.56% | 2.77B | |
| -8.47% | 2.25B | |
| -1.86% | 1.95B |
- Stock Market
- Equities
- CSTL Stock